Pathology: mML - L2 - all population; mML - NA - all population;
mML - L2 - all population | mML - NA - all population | |||||||||
Ascierto (ipi 10 vs 3 mg/kg), 2017 | CA184-004, 2011 | MDX010 Ipi vs gp100, 2010 | MDX010 Ipi plus gp100 vs gp100, 2010 | MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 | CA184-024, 2011 | E1609 (ipi10), 2020 | EORTC 18071, 2015 | E1609 (ipi3), 2020 | ||
Ipilimumab (10 mg/kg) | 4 | T1 | T1 | T1 | T1 | |||||
ipilimumab alone | 2 | T0 | T0 | T1 | T0 | T1 | ||||
ipilimumab plus gp100 | 2 | T1 | T1 | |||||||
ipilimumab plus SoC | 1 | T1 | ||||||||
interferon alpha | 0 | T0 | T0 | |||||||
placebo | 0 | T0 | ||||||||
placebo plus SoC | 0 | T0 | ||||||||
gp100 | 0 | T0 | T0 |